Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence

Y Okumura; R Nishimura; K Nakatsukasa; A Yoshida; N Masuda; M Tanabe; T Shien; S Tanaka; N Arima; Y Komoike; T Taguchi; T Iwase; H Inaji; M Ishitobi; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

doi:10.1016/j.ejso.2015.01.030

Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence

Eur J Surg Oncol. 2015 Apr;41(4):548-52. doi: 10.1016/j.ejso.2015.01.030. Epub 2015 Feb 7.

Authors

Affiliations

¹ Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan.
² Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
³ Dept. of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan.
⁴ Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
⁵ Division of Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
⁶ Dept. of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
⁷ Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan.
⁸ Dept. of Pathology, Kumamoto City Hospital, Kumamoto, Japan.
⁹ Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
¹⁰ Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. Electronic address: [email protected].

PMID: 25682910
DOI: 10.1016/j.ejso.2015.01.030

Abstract

Introduction: Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery.

Patients and methods: A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR.

Results: There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test).

Conclusion: An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.

Keywords: Breast cancer; Ipsilateral breast tumor recurrence; Ki-67.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Biomarkers, Tumor / analysis*
Breast Neoplasms / chemistry*
Breast Neoplasms / pathology*
Breast Neoplasms / surgery
Disease-Free Survival
Female
Humans
Immunohistochemistry
Ki-67 Antigen / analysis*
Mastectomy, Segmental
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local / chemistry*
Neoplasm Recurrence, Local / pathology*
Neoplasm Recurrence, Local / surgery
Receptor, ErbB-2 / analysis*
Receptors, Estrogen / analysis*

Substances

Biomarkers, Tumor
Ki-67 Antigen
Receptors, Estrogen
ERBB2 protein, human
Receptor, ErbB-2